About This Project
The problem with cancer drugs today is they harm both normal and cancer cells. I've designed a drug that specifically inhibits F1F0 ATP hydrolysis, an enzyme operating mode that cancer cells rely on to survive, that normal cells do not rely on. My hypothesis is that that when treated with my drug, cancer cells will die while normal cells will survive. To test my hypothesis, the drug will be manufactured and tested at the National Cancer Institute.
Ask the ScientistsJoin The Discussion
What is the context of this research?
The problem with today's cancer drugs is they harm both cancer and normal cells. I was inspired to design a drug that specifically inhibits F1F0 ATP hydrolysis because I've shown prior and previously that this is an enzyme operating mode that cancer cells specifically rely on to survive and multiply, which normal cells don't rely on. I hypothesize that when treated with my drug, cancer cells will die while normal cells will be unaffected. To test this, I will manufacture my drug through Wuxi Apptec and send the drug to the National Cancer Institute to test against 59 different cancer cell lines from 9 different tissues. If successful, the drug will show the ability to slow the proliferation of cancer. Further detail on NCI testing is here.
What is the significance of this project?
If my drug that specifically inhibits F1F0 ATP hydrolysis can kill cancer cells while keeping normal cells unharmed, this drug could advance as a new cancer drug candidate. The holy grail of cancer treatments is a drug that can kill cancer cells while having no effect on normal cells. Research shows that, presently, it is the cancer drug itself that kills some cancer patients. My newly designed drug offers an opportunity to selectively kill cancer cells.
What are the goals of the project?
I hypothesize that this drug that specifically inhibits F1F0 ATP hydrolysis will be able to kill cancer cells while leaving normal cells unharmed. To test this, my drug will be synthesized by the chemical synthesis company Wuxi Apptec. Once synthesized, the drug will be sent to National Cancer Institute to test its anti-cancer activity. The results of the testing will be shared in an open access peer-reviewed journal and sent to backers. Backers will be acknowledged by name in this article.
I have a collaboration with the National Cancer Institute to test the anti-cancer activity of my newly designed drug. The funding from this campaign will go towards synthesizing the drug through the chemical synthesis company Wuxi Apptec. Because National Cancer Institute is one of my collaborators there is no charge for anti-cancer testing.
Firstly, the drug will be synthesized, from my design, by a chemical synthesis company called Wuxi Apptec. Then this drug will be sent to the National Cancer Institute where it will be tested for anti-cancer activity. The results of this testing will be returned to myself. I will then disseminate these results by writing them up into a paper, which will subsequently be shared with backers and published in an open access peer-reviewed journal.
Dec 13, 2018
The drug will be synthesized, from my design, by a contract chemical synthesis company called Wuxi Apptec.
Jan 13, 2019
This drug will then be sent to the National Cancer Institute. Where it will be tested for anti-cancer activity.
Apr 15, 2019
May 01, 2019
The anti-cancer activity test results will be returned to myself.
Dec 31, 2019
The results will be shared with backers and published in an open access peer reviewed scientific journal.
Meet the Team
Dr. Michael Forrest
I earned my undergrad degree in biochemistry at Cambridge University and my Ph.D. in computer science. I have 7 years experience in disease biology research. An example of one of my peer-reviewed scientific publications is here.
One of my discoveries is that a drug for treating emphysema, almitrine, has anticancer efficacy. Disclosed here. In vitro, in independent anti-cancer testing at the National Cancer Institute (USA), almitrine outperforms many present cancer drugs (e.g. carboplatin) and has already been shown extremely safe in humans, with less side-effects than all present cancer drugs. Almitrine is accumulated at high concentration in the lungs. One of my near-term objectives is to get almitrine into human trials for lung cancer (NSCLC).
Nothing posted yet.
This picture shows the anti-cancer performance of a new cancer drug that I've designed, named BT1. It is shown in comparison with a currently used cancer drug called carboplatin. Now I request funding to synthesize and test another drug that I've designed, which I predict will work even better.
- $1,915Total Donations
- $112.65Average Donation